Evidence map›Paper›PMID 34926774›Full record

ArticleGynecologic oncology reports2021

Neoadjuvant chemotherapy for Ewing's sarcoma family tumors of the uterine cervix: A case report.

Masahiko Mori, Kazunori Honda, Hirofumi Tsubouchi, Jun Sakata, Seiichi Kato, Shiro Suzuki

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Ewing sarcoma of the uterus: A case report.Case reports in women's health · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Masahiko MoriDepartment of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Kazunori HondaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hirofumi TsubouchiDepartment of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Jun SakataDepartment of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Seiichi KatoDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Shiro SuzukiDepartment of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Aichi Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing's sarcoma family tumors of the uterine cervix are extremely rare and, thus, an optimal treatment strategy has not yet been established. To the best of our knowledge, 28 cases were reported in the English literature between 1996 and 2020, and treatments involved surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiotherapy. The vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VDC-IE) protocol increased the survival rate of patients with non-metastatic Ewing's sarcoma family tumors. We herein present a case of a Ewing's sarcoma family tumor of the cervix in a one-month postpartum woman treated with neoadjuvant chemotherapy using the VDC-IE protocol and radical hysterectomy followed by adjuvant chemotherapy, and discussed the diagnosis and treatment of this tumor through a literature review.

Indexed as

CD99ESWR1 gene rearrangementNeoadjuvant chemotherapyRadical hysterectomyVDC-IE

Identifiers

PMID34926774
PMCPMC8651897
OpenAlexW3217479668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.